Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in Advanced Malignancies and NSCLC
NCT01449461Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Sep 2011
- Primary completion
- Nov 2015
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of brigatinib in non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma (DLBCL) and 1 more (6 arms), sponsored by ARIAD Pharmaceuticals, Inc. Primary endpoints: Recommended Phase 2 Dose at 28 days and Objective Response Rate up to 8.4 years. Started Sep 2011; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)anaplastic large cell lymphoma (ALCL)diffuse large B-cell lymphoma (DLBCL)inflammatory myofibroblastic tumor (IMT)
Beyond the preview
Go deeper on NCT01449461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01449461.